文献速递造血干细胞移植与细胞治疗

异基因造血细胞移植后第三方粪菌移植重建微生物组多样性

Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.
PubMed 文献 · Blood Adv · 2018-01-01

这项开放标签单组先导研究纳入18例拟接受异基因造血细胞移植者,计划移植后经口给予第三方粪菌移植胶囊。13例实际在中位27天(范围19-45天)后接受粪菌移植,全部能吞服并耐受所有胶囊,达到可行性主要终点。粪菌移植耐受良好,出现1例治疗相关显著不良事件(腹痛);12个月总生存率和无进展生存率均为85%(95%CI 51%-96%)。

要点

  • 18例入组、13例在中位27天(范围19-45天)后接受第三方粪菌移植,全部吞服并耐受所有胶囊,达到可行性主要终点。
  • 粪菌移植耐受良好,出现1例治疗相关显著不良事件(腹痛);2例后续发生急性胃肠道GVHD,其中1例合并菌血症。
  • 粪菌移植后12个月总生存率和无进展生存率均为85%(95%CI 51%-96%),12个月非复发死亡率为8%(95%CI 0%-30%)。

核心结论

  • 异基因造血细胞移植后经验性第三方粪菌移植似乎是可行的、安全的,并与受者微生物组多样性扩增相关。

研究设计与样本

  • 开放标签单组先导研究,18例在异基因造血细胞移植前入组,计划接受第三方粪菌移植胶囊。
  • 粪菌移植在中性粒细胞植入后不晚于4周内给予,粪菌移植前48小时内不允许使用抗生素。

主要发现

  • 5例未接受粪菌移植:3例因粪菌移植前发生早期急性胃肠道GVHD,1例因持续性移植相关胃肠道毒性,1例因患者决定。
  • 13例在中位27天(范围19-45天)后接受粪菌移植,参与者能吞服并耐受所有粪菌移植胶囊,达到可行性主要终点。
  • 粪菌移植耐受良好,出现1例治疗相关显著不良事件(腹痛);2例后续发生急性胃肠道GVHD,其中1例同时有菌血症;无其他菌血症病例。
  • 存活者中位随访15个月(范围13-20个月);粪菌移植后12个月总生存率和无进展生存率的Kaplan-Meier估计均为85%(95%CI 51%-96%)。
  • 1例非复发死亡由急性胃肠道GVHD导致,12个月非复发死亡率为8%(95%CI 0%-30%)。

关键数值与推荐

  • 可行性主要终点:参与者能吞服并耐受所有粪菌移植胶囊。
  • 粪菌移植给予时间:中性粒细胞植入后不晚于4周;粪菌移植前48小时内不允许使用抗生素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We hypothesized that third-party fecal microbiota transplantation (FMT) may restore intestinal microbiome diversity after allogeneic hematopoietic cell transplantation (allo-HCT). In this open-label single-group pilot study, 18 subjects were enrolled before allo-HCT and planned to receive third-party FMT capsules. FMT capsules were administered no later than 4 weeks after neutrophil engraftment, and antibiotics were not allowed within 48 hours before FMT. Five patients did not receive FMT because of the development of early acute gastrointestinal (GI) graft-versus-host disease (GVHD) before FMT (n = 3), persistent HCT-associated GI toxicity (n = 1), or patient decision (n = 1). Thirteen patients received FMT at a median of 27 days (range, 19-45 days) after HCT. Participants were able to swallow and tolerate all FMT capsules, meeting the primary study endpoint of feasibility. FMT was tolerated well, with 1 treatment-related significant adverse event (abdominal pain). Two patients subsequently developed acute GI GVHD, with 1 patient also having concurrent bacteremia. No additional cases of bacteremia occurred. Median follow-up for survivors is 15 months (range, 13-20 months). The Kaplan-Meier estimates for 12-month overall survival and progression-free survival after FMT were 85% (95% confidence interval, 51%-96%) and 85% (95% confidence interval, 51%-96%), respectively. There was 1 nonrelapse death resulting from acute GI GVHD (12-month nonrelapse mortality, 8%; 95% confidence interval, 0%-30%). Analysis of stool composition and urine 3-indoxyl sulfate concentration indicated improvement in intestinal microbiome diversity after FMT that was associated with expansion of stool-donor taxa. These results indicate that empiric third-party FMT after allo-HCT appears to be feasible, safe, and associated with expansion of recipient microbiome diversity. This trial was registered at www.clinicaltrials.gov as #NCT02733744.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. DeFilipp Z, Peled JU, Li S, et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv. 2018. PMID: 29592876. doi:10.1182/bloodadvances.2018017731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。